170 related articles for article (PubMed ID: 32178826)
21. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
22. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
23. Humanized mouse models for immuno-oncology research.
Chuprin J; Buettner H; Seedhom MO; Greiner DL; Keck JG; Ishikawa F; Shultz LD; Brehm MA
Nat Rev Clin Oncol; 2023 Mar; 20(3):192-206. PubMed ID: 36635480
[TBL] [Abstract][Full Text] [Related]
24. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
Saito R; Kobayashi T; Kashima S; Matsumoto K; Ogawa O
Int J Clin Oncol; 2020 May; 25(5):831-841. PubMed ID: 31407168
[TBL] [Abstract][Full Text] [Related]
25. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
26. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
27. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
[TBL] [Abstract][Full Text] [Related]
28. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
29. Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors.
Lanis JM; Lewis MS; Strassburger H; Larsen K; Bagby SM; Dominguez ATA; Marín-Jiménez JA; Pelanda R; Pitts TM; Lang J
J Vis Exp; 2022 Dec; (190):. PubMed ID: 36591990
[TBL] [Abstract][Full Text] [Related]
30. Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.
Chen A; Neuwirth I; Herndler-Brandstetter D
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296949
[TBL] [Abstract][Full Text] [Related]
31. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
32. A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research.
Li Z; Yang X; Zhang Y; Yang X; Cui X; Zhang Y; Gong W; Bai H; Liu N; Tang Z; Guo M; Li K; Zhang T; Wang L; Song X
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475974
[TBL] [Abstract][Full Text] [Related]
33. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
34. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.
Sanmamed MF; Chester C; Melero I; Kohrt H
Ann Oncol; 2016 Jul; 27(7):1190-8. PubMed ID: 26912558
[TBL] [Abstract][Full Text] [Related]
35. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
36. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
37. Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.
Chiorazzi M; Martinek J; Krasnick B; Zheng Y; Robbins KJ; Qu R; Kaufmann G; Skidmore Z; Juric M; Henze LA; Brösecke F; Adonyi A; Zhao J; Shan L; Sefik E; Mudd J; Bi Y; Goedegebuure SP; Griffith M; Griffith O; Oyedeji A; Fertuzinhos S; Garcia-Milian R; Boffa D; Detterbeck F; Dhanasopon A; Blasberg J; Judson B; Gettinger S; Politi K; Kluger Y; Palucka K; Fields RC; Flavell RA
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37487666
[TBL] [Abstract][Full Text] [Related]
38. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.
Morton JJ; Bird G; Refaeli Y; Jimeno A
Cancer Res; 2016 Nov; 76(21):6153-6158. PubMed ID: 27587540
[TBL] [Abstract][Full Text] [Related]
39. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
[TBL] [Abstract][Full Text] [Related]
40. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
Song Y; Liu Q; Zuo T; Wei G; Jiao S
Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
